Welcome international healthcare professionals

Welcome, this website is intended for healthcare professionals with an interest in the treatment of Melanoma. By clicking the button below you are declaring and confirming that you are a healthcare professional.


Welcome to the European Journal of Cancer’s Advances in Melanoma Resource Centre.

The Resource Centre, edited by Prof. Reinhard Dummer, Dr. Paolo Ascierto and Dr. James Larkin, will provide you with the latest research on melanoma, including a selection of original research and review articles from some of the world’s leading journals, case studies, and other educational material.

New articles will be added to the Resource Centre regularly and are openly available to our readers.

Paper of the month – November 2014

  • Editorial comment by Prof. R. Dummer:
    This month we have decided to present two papers. Both papers were published in the New England Journal of Medicine and report on two prospective randomized trials investigating the clinical outcome of a monotherapy with a BRAF inhibitor versus a combination therapy using a BRAF inhibitor and a MEK inhibitor in patients with BRAF mutated advanced melanoma. In both studies there is a clear advantage for the combination therapy with an increase in progression free survival resulting in an improvement of approximately 40% with an improved response rate. The phase III clinical trial presented by Long reached its primary endpoint progression free survival and the secondary endpoint overall survival. Taking together these studies clearly support combination therapy with a BRAF and MEK inhibitor as the standard of care for BRAF mutated melanoma.

    Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    Georgina V. Long, M.D., Ph.D., Daniil Stroyakovskiy, M.D., Helen Gogas, M.D., Evgeny Levchenko, M.D., Filippo de Braud, M.D., James Larkin, M.D., Claus Garbe, M.D., Ph.D., Thomas Jouary, M.D., Axel Hauschild, M.D., Ph.D., Jean Jacques Grob, M.D., Ph.D., V

    N Engl J Med 2014; 371:1877-1888November 13, 2014DOI: 10.1056/NEJMoa1406037
  • Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

    James Larkin, M.D., Ph.D., Paolo A. Ascierto, M.D., Brigitte Dréno, M.D., Ph.D., Victoria Atkinson, M.D., Gabriella Liszkay, M.D., Michele Maio, M.D., Mario Mandalà, M.D., Lev Demidov, M.D., Daniil Stroyakovskiy, M.D., Luc Thomas, M.D., Ph.D., Luis de la

    N Engl J Med 2014; 371:1867-1876November 13, 2014DOI: 10.1056/NEJMoa1408868

Latest articles

About the editors





Register to our E-Alert to stay informed of new clinical research and cases published on this platform.

Event planner

Featured videos

Watch the videos from Reinhard Dummer, Dirk Schadendorf, Veronique del Marmol and Christian Blank.

Search this site

Search form